Autonomix Medical, Inc. announced on June 30, 2025, that the first patient has been enrolled and treated in the follow-on phase of its proof-of-concept human clinical trial (PoC 2). This phase evaluates the safety and effectiveness of delivering transvascular energy to ablate problematic nerves and mitigate cancer pain.
The PoC 2 study represents a market expansion opportunity, building on the positive results from the initial PoC 1 phase in patients with severe pancreatic cancer pain. This expansion aims to double the potential addressable market by evaluating additional visceral cancers that signal pain through the Celiac Plexus, as well as earlier-stage pancreatic cancers.
CEO Brad Hauser stated that the start of patient treatment in the PoC 2 study is a major milestone that reinforces the company's momentum and marks a critical step toward unlocking substantial clinical and commercial potential. The PoC 2 phase will focus on interventional cancer pain management applications like pancreatic, gall bladder, liver, and bile duct cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.